SLC5A2 and diabetic kidney disease: SGLT2 inhibitors can also reduce glomerular intracapsular pressure through a mechanism of “tubuloglomerular feedback,” which achieves a similar effect in terms of reducing urinary protein in diabetic nephropathy (34).